OSN [Ossen Innovation] 6-K: Ossen Innovation Enters into Non-Binding Letter of Intent
[Ossen Innovation Enters into Non-Binding Letter of Intent with America-Asia Diabetes Research Upon completion of the Acquisition, the Company would indirectly own 90.27% of San MediTech. San MediTech's proprietary Dynamic Glucose Monitoring System ("DGMS") provides continuous, real-time monitoring of glucose level in diabetes patients, with two patents granted in China and several patents pending both in China and the U.S.] [FORM 6-K OSSEN INNOVATION CO., LTD. 518 SHANGCHENG ROAD, FLOOR 17, SHANGHAI, 200120, PEOPLE’S REPUBLIC OF CHINA Form 20-F x Form 40-F ¨ Yes ¨ No x OSSEN INNOVATION CO., LTD. Number Description 99.1 Press Release, dated July 8, 2016 6-K 1 v443938_6k.htm FORM 6-K]